<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>Fecal Microbiota Transplantation - 2021 Update</title>
    <meta charset="utf-8" />
    <meta name="author" content="Brendan J. Kelly, MD, MS" />
    <meta name="date" content="2021-03-25" />
    <link href="libs/tile-view/tile-view.css" rel="stylesheet" />
    <script src="libs/tile-view/tile-view.js"></script>
    <script src="libs/xaringanExtra-webcam/webcam.js"></script>
    <script id="xaringanExtra-webcam-options" type="application/json">{"width":"200","height":"200","margin":"1em"}</script>
    <link href="libs/tachyons/tachyons.min.css" rel="stylesheet" />
    <link href="libs/animate.css/animate.xaringan.css" rel="stylesheet" />
    <script src="libs/clipboard/clipboard.min.js"></script>
    <link href="libs/shareon/shareon.min.css" rel="stylesheet" />
    <script src="libs/shareon/shareon.min.js"></script>
    <link href="libs/xaringanExtra-shareagain/shareagain.css" rel="stylesheet" />
    <script src="libs/xaringanExtra-shareagain/shareagain.js"></script>
    <link rel="stylesheet" href="xaringan-themer-blue-grids-fade.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">

exclude: true




---
background-image: url(img/cdiff_flip_dark.png)
background-size: cover
class: middle left hide-count

.fade-in[
# &lt;span style='color:white'&gt;Fecal Microbiota Transplantation&lt;/span&gt;
]
.fade-in[
.callout-url-leftcorner[
&lt;span style='font-size:0.75em;font-weight:bold;color:white'&gt;
Brendan J. Kelly, MD, MS  
Infectious Diseases &amp; Epidemiology  
University of Pennsylvania  
&lt;/span&gt;
&lt;span style='font-size:0.5em;font-weight:bold;color:white;'&gt;
25 March 2021
&lt;/span&gt;
]
]

---

# Disclosures  

.pad-left[

- None  
  
]



---
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-a animated flipInY"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;


---
layout: false
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-a"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-b animated flipInX"&gt;&lt;div&gt;FMT @Penn&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;


---
layout: false
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-a"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-b"&gt;&lt;div&gt;FMT @Penn&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-c animated bounceInDown"&gt;&lt;div&gt;Applications&lt;br&gt;in Oncology&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;



---
layout: false
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-a"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-grey"&gt;&lt;div&gt;FMT @Penn&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-grey"&gt;&lt;div&gt;Applications&lt;br&gt;in Oncology&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;



---

# Fecal Microbiota Transplantation (FMT)

.pad-left[

- Transplant fecal microbiota from healthy donor to colon of recipient  
  
- &lt;u&gt;Methods&lt;/u&gt;: frozen oral capsules, solution via enteric tube, enema, colonoscopy  

- &lt;u&gt;Indications&lt;/u&gt;:

    - _C. difficile_ infection (CDI) = driving force behind development  
    
    - MDRO colonization    
    
    - inflammatory bowel disease (IBD)  
    
    - oncology: auto-FMT post allo-SCT; immune checkpoint inhibitors; GVHD  


]


---

# _Clostridioides difficile_ Infection

.pad-left[

- Infectious colitis that occurs after antibiotic treatment ("antibiotic-associated")  

- Depletion of protective taxa (abx &amp; PPI) ⇾ altered bile acid metabolism ⇾ germination of resident or recently ingested _C. difficile_ spores ⇾ expansion of vegetative _C. difficile_ ⇾ toxin production ⇾ colonic inflammation ⇾ CDI

- Treatment with anti-CDI antibiotics (vancomycin, fidaxomicin) contributes to persistent depletion of protective taxa ⇾ risk for recurrent CDI

- **FMT restores colonization resistance by restoring protective taxa**

- &lt;u&gt;Note&lt;/u&gt;: treatment with anti-CDI antibiotics is prerequisite

]


---
background-image: url(img/tariq_2fmt_forest_plot.png)
background-size: 900px
background-position: 50% 35%


.footnote[Tariq R et al _Clin Inf Dis_ 2019]



---
background-image: url(img/cdiff_idsa_guideline_2017_fmt.png)
background-size: 900px
background-position: 50% 35%


.footnote[IDSA/SHEA Guidelines: McDonald LC et al _Clin Inf Dis_ 2018]


---

# Efficacy Despite Product Heterogeneity?

.pad-left[

- FMT contains multitudes:  

    - bacteria, fungi, archaea... bacteriophage, eukaryotic viruses (e.g., TTVs) ...
    
     ... human colonocytes, metabolites

- Causal models for efficacy versus _C. difficile_ infection:  

    - Direct bacterial interaction? Bile acid metabolism-mediated interaction?  

    - Bile acid metabolism &amp; Th17 regulatory cells?  

- **We do it because it works, but we don't know why!**

]

.footnote[Bojanova &amp; Bordenstein _PLoS Biology_ 2016; Ott et al _Gastroenterology_ 2017; Hang et al _Nature_ 2019]


---

# FMT Regulation &amp; Commercial Alternatives

.pad-left[

- **Guideline-recommended for CDI but no FDA-approved product**:

    - IND required for non-CDI indications

    - for CDI, FDA exercises "enforcement discretion"

    - concern that product availability (e.g., OpenBiome) limiting RCT enrollment

- Multiple companies with "ecobiotic" FMT alternatives in phase 2/3 trials:  

    - Finch, Rebiotix, Seres, Vedanta  
    
    - May 2020: "Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial"


]


---
layout: false
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-grey"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-b animated flipInY"&gt;&lt;div&gt;FMT @Penn&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-grey"&gt;&lt;div&gt;Applications&lt;br&gt;in Oncology&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;


---

# FMT Program Development at Penn

.pad-left[

- &lt;u&gt;2014-2016&lt;/u&gt;: ID Division Stool Bank  

    - FDA enforcement discretion (no IND)
    
    - 67 FMTs: 82% aggregate cure rate
  
- &lt;u&gt;2016-2018&lt;/u&gt;: OpenBiome partnership  

- &lt;u&gt;2019-present&lt;/u&gt;: "Penn Microbiome Therapy (PMT)"  

    - IND for 3 products: capsule, upper GI liquid, enema  
    
    - 3 protocols: R-CDI, SC-CDI, postpartum incontinence (OB-GYN: Uduak Andy, PI)  
    
      (compassionate use for MDRO colonization)

]


---

# Impact of COVID-19 on FMT at Penn

.pad-left[

- **FDA partial hold**: all doses manufactured after December 1, 2019

- Adequate donor/dose screening:

    - challenges with stool testing for SARS-CoV-2 (high LOD)
    
    - donor screening with serology? NP NAAT?

- Ongoing COVID-19 activity slows (already slow) clinical trial enrollment

- **Recent resumption of enrollment for all protocols**

]



---
layout: false
class: full-screen hide-count

&lt;div class="grid-3-1"&gt;
&lt;div class="extension-tile gridset-grey animated"&gt;&lt;div&gt;What &amp; Why?&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-grey animated"&gt;&lt;div&gt;FMT @Penn&lt;/div&gt;&lt;/div&gt;
&lt;div class="extension-tile gridset-c animated flipInX"&gt;&lt;div&gt;Applications&lt;br&gt;in Oncology&lt;/div&gt;&lt;/div&gt;
&lt;/div&gt;



---
background-image: url(img/peled_nejm_2020.png)
background-size: 1000px
background-position: 50% 60%

# Dysbiosis &amp; Death


.footnote[Peled et al _NEJM_ 2020]



---
background-image: url(img/taur_diversity_vs_engraftment.png)
background-size: 800px
background-position: 50% 50%

# Auto-FMT Post Allo-SCT

.footnote[Taur et al _Sci Trans Med_ 2018]


---
background-image: url(img/taur_fmt_taxa.png)
background-size: 600px
background-position: 50% 60%


.footnote[Taur et al _Sci Trans Med_ 2018]


---

# FMT &amp; Immune Checkpoint Inhibitors

.pad-left[

- Differential bacterial signatures of ICI responders versus non-responders

- Modulation of the gut microbiome via FMT from patients alters antitumor immunity and response to ICI therapy in gnotobiotic mice

- FMT also applied to &amp; resolves ICI-related colitis: 

    - variable (donor-dependent) effects on microbiome  
    
    - increase proportion of regulatory T-cells in colonic mucosa  

]
    
.footnote[Routy et al _Science_ 2018; Gopalakrishnan et al _Science_ 2018; Matson et al _Science_ 2018; Wang et al _Nat Med_ 2018]


---

# FMT &amp; GVHD  

.pad-left[

- Disruption of intestinal microbiota associated with GVHD

- Recent prospective single-arm study:  

    - 15 post-allo-HCT with steroid-dependent, acute or late-onset acute intestinal GvHD

    - effect of donor FMT on GVHD symptoms and biomarkers  
    
    - 10 of 15 study participants with complete clinical response observed within 1 month after FMT, without additional interventions to alleviate GVHD symptoms
    
    - associated increase in gut microbial alpha-diversity, a partial engraftment of donor bacterial species, and increased abundance of butyrate-producing bacteria, including _Clostridiales_ and _Blautia_ species
    
]
    
.footnote[van Lier et al _Sci Trans Med_ 2020]



---

# Risks of FMT in Oncology Patients  

.pad-left[

- Disseminated bacterial infection:

    - ESBL _E. coli_ sepsis and death*  
    
- CMV &amp; EBV:

    - CMV colitis post-FMT has been reported  
    
    - risk of CMV listed on informed consent for our PMT prooducts
    
      (donors are screened for CMV/EBV but not restricted)

- GVHD: given heterogeneity of FMT, potential for exacerbation?  
  
]

.footnote[*DeFilipp et al _NEJM_ 2019]



---
class: middle center hide-count
background-image: url(img/cdiff_flip_dark.png)
background-size: cover

# &lt;span style='color:white'&gt;Questions?&lt;/span&gt;

 &lt;!-- .callout-url-bottom[  
.fade-in[&lt;span style="font-size:0.5em; color:white"&gt;slides ↓ &lt;/span&gt;]  
&lt;span style="link-color:white"&gt;[bjklab.org](http://www.bjklab.org)&lt;/span&gt;  
] --&gt;
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="libs/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"ratio": "16:9",
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false,
"slideNumberFormat": "%current%"
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
